Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector newsTweets
Most relevant news about GILEAD SCIENCES
02/22GILEAD SCIENCES : Announces Senior Management Change
BU
02/22SANGAMO THERAPEUTICS : Surges on Therapy Collaboration Deal with Kite -- Market ..
DJ
02/22Sangamo in $3 billion gene-editing deal with Gilead
RE
02/22GILEAD SCIENCES : Kite, a Gilead Company, And Sangamo Therapeutics Announce Coll..
PR
02/12GILEAD SCIENCES : to Present at the RBC Capital Markets 2018 Global Healthcare C..
AQ
02/12PFIZER : ViiV Healthcare files patent infringement litigation against Gilead Sci..
AQ
02/09GILEAD SCIENCES : Glaxo sues US firm for allegedly infringing on HIV drug patent
AQ
02/08GILEAD SCIENCES : to Present at the RBC Capital Markets 2018 Global Healthcare C..
BU
02/08FTSE slides after BOE meeting as pound pops higher
RE
02/08GILEAD SCIENCES : Announces Fourth Quarter and Full Year 2017 Financial Results
AQ
02/08GILEAD SCIENCES : Announces 10 Percent Increase in First Quarter 2018 Dividend
AQ
02/08GILEAD SCIENCES : U.S. Food and Drug Administration Approves Gilead's Biktarvy f..
AQ
02/08GILEAD SCIENCES : And Sage Therapeutics Just Picked Up Big FDA Decisions
AQ
02/08GILEAD SCIENCES : FDA approves Gilead's triple combo HIV therapy
AQ
02/07GILEAD SCIENCES : U.S. Food and Drug Administration Approves Gilead’s Bikt..
BU
More most relevant news
All news about GILEAD SCIENCES
02/24GILEAD SCIENCES : Fish & Richardson Wipes Out $2.5 Billion Patent Verdict Agains..
AQ
02/23GILEAD SCIENCES' : Trademark Application for "SIMPLY POWERFUL" Filed
AQ
02/23GILEAD SCIENCES : An Application for the Trademark "AZLI" Has Been Filed by Gile..
AQ
02/23GILEAD SCIENCES : Trademark Application for "LETAIRIS" Filed by Gilead Sciences
AQ
02/22GILEAD SCIENCES : Announces Senior Management Change
BU
02/22SANGAMO THERAPEUTICS : Surges on Therapy Collaboration Deal with Kite -- Market ..
DJ
02/22Sangamo in $3 billion gene-editing deal with Gilead
RE
02/22GILEAD SCIENCES : Kite, a Gilead Company, And Sangamo Therapeutics Announce Coll..
PR
02/21GILEAD SCIENCES : Wired News - Gilead Sciences Rejoices as Federal Judge Reverse..
AC
02/15GILEAD SCIENCES : New Data from Gilead Sciences Illuminate Findings in Antiretro..
AQ
More news
Sector news : Bio Therapeutic Drugs
02/23SANOFI : Says U.S. Waiting Period for Bioverativ Has Expired
DJ
02/22Sangamo in $3 billion gene-editing deal with Gilead
RE
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
02/23Gilead withdraws application in Europe for expanded use of Zydelig 
02/23YOUR DAILY PHARMA SCOOP : Dynavax Achieves Major Milestone, GW Pharmaceuticals G.. 
02/23SORRENTO THERAPEUTICS : Will This Novel CAR-T Deliver Robust Value? 
02/23U.S. BIOTECH/PHARMA SECTOR DAILY OBS : February 22, 2018 
02/22SANGAMO THERAPEUTICS : Great Start To 2018 - $3 Billion KITE Announcement 
02/22Sangamo up 6% premarket on Gilead deal to develop oncology-focused cell thera.. 
Latest Tweets
02/24Gilead Sciences $GILD Earns Market Perform Rating from Leerink Swann  
02/24Gilead is betting big on gene editing to bolster its cell-based immunotherapy..
1
02/24Gilead loses its head of commercial ops as it takes on daunting sales challen.. 
02/24In focus: $AAPL $GOOGL $NVDA $MSFT $GILD $DIS Join us. "A volatile market c..
8
02/24Top 5 for the week: #1 - the gene editing surprise -- All in: Gilead maps a $..
9
More tweets
Qtime:426
Financials ($)
Sales 2018 21 270 M
EBIT 2018 11 296 M
Net income 2018 6 975 M
Debt 2018 16 887 M
Yield 2018 2,79%
P/E ratio 2018 15,36
P/E ratio 2019 14,46
EV / Sales 2018 5,75x
EV / Sales 2019 5,66x
Capitalization 105 B
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 88,8 $
Spread / Average Target 10%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES10.83%105 375
VERTEX PHARMACEUTICALS5.16%39 931
REGENERON PHARMACEUTICALS-16.00%34 113
BIOVERATIV INC93.43%11 243
GENMAB16.62%10 343
BLUEBIRD BIO INC12.97%10 168